血液疾患に合併した発熱性好中球減少症に対するmeropenem 1g1日3回投与の臨床的有用性

摘要

BACKGROUND: Febrile neutropenia (FN) is a very important causeof mortality in patients receiving intensive chemotherapy. In2010 meropenem (MEPM) 3g per day was approved for the treatmentof FN in Japan, however, there are not enough reports about 3gusage of MEPM in Japanese patients yet. OBJECTIVE: This studyassessed the clinical efficacy and safety of MEPM 1g three timesa day as empirical monotherapy for FN in hematological patients.METHODS: This is the retrospective cohort study involvedinpatients at Fukui university hospital. Fifty-six patientsreceived 3g MEPM from January 2010 to January 2011. The mean agewas 64.2. The underlying diseases were acute leukemia in 33 cases,malignant lymphoma in 15 and myelodysplastic syndrome in 8.RESULTS: The response rate was 80% (excellent response: 62%, goodresponse: 18%, minor response: 16%, no response: 4%). The febrileduration was average 4.18 days. Treatment did not need to bediscontinued or interrupted due to adverse events in any of thepatients. CONCLUSIONS: This study suggests that MEPM 1g threetimes per day is useful and tolerable therapy in Japanese FN patients.